Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.46 |
| ▸ | FLT1 | P17948 | 5/20 | 0.46 |
| ▸ | FLT4 | P35916 | 3/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 6/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325243 | 0.89 | KDR (0.59) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1325055 | 0.89 | KDR (0.60) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1324097 | 0.88 | KDR (0.51) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL12124621 | 0.87 | KDR (0.52) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2471560 | 0.87 | KDR (0.61) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1324999 | 0.86 | KDR (0.49) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1325008 | 0.85 | KDR (0.59) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1324053 | 0.85 | KDR (0.43) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1323994 | 0.84 | KDR (0.42) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL1324228 | 0.83 | KDR (0.48) | KDRFLT1FLT4RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058276-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | claimed |
| US-8058276-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |